Canaccord Genuity Group Forecasts Strong Price Appreciation for Heartflow (NASDAQ:HTFL) Stock

Heartflow (NASDAQ:HTFL) had its price target hoisted by analysts at Canaccord Genuity Group from $40.00 to $43.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price target would suggest a potential upside of 65.26% from the stock’s current price.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Heartflow in a report on Monday, December 29th. Wells Fargo & Company reduced their target price on shares of Heartflow from $38.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Heartflow presently has an average rating of “Moderate Buy” and an average price target of $37.67.

Heartflow Stock Performance

Shares of NASDAQ:HTFL opened at $26.02 on Thursday. The business has a fifty day moving average of $26.86 and a 200-day moving average of $30.41. Heartflow has a twelve month low of $20.13 and a twelve month high of $41.22. The firm has a market cap of $2.23 billion and a PE ratio of -14.38.

Insider Buying and Selling

In other Heartflow news, insider Campbell Rogers sold 65,153 shares of the stock in a transaction dated Thursday, February 12th. The stock was sold at an average price of $24.49, for a total value of $1,595,596.97. Following the transaction, the insider owned 76,034 shares of the company’s stock, valued at approximately $1,862,072.66. This represents a 46.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Julie A. Cullivan sold 9,122 shares of the firm’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $25.00, for a total value of $228,050.00. Following the transaction, the director owned 27,291 shares in the company, valued at approximately $682,275. This trade represents a 25.05% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 2,127,399 shares of company stock worth $59,295,771.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd bought a new stake in Heartflow in the fourth quarter valued at approximately $27,000. TFC Financial Management Inc. bought a new position in shares of Heartflow during the third quarter worth $40,000. Russell Investments Group Ltd. acquired a new position in shares of Heartflow in the 4th quarter valued at $45,000. Legal & General Group Plc bought a new stake in shares of Heartflow in the 3rd quarter valued at $59,000. Finally, Strs Ohio acquired a new stake in Heartflow during the 4th quarter worth $99,000.

Heartflow News Summary

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Q4 revenue beat and strong top‑line growth — HeartFlow reported revenue of $49.13M vs consensus $46.58M, up ~40.5% year‑over‑year, signaling accelerating adoption and top-line momentum. MarketBeat: Q4 results & transcript
• Positive Sentiment: Bullish analyst move — Canaccord raised its price target to $43 and maintained a Buy rating, implying a sizable upside and providing supportive institutional sentiment. Benzinga: Canaccord price target raise
• Neutral Sentiment: Analysts cut targets but stayed positive — JPMorgan lowered its PT from $40 to $35 but kept an Overweight rating, signaling confidence in the business even while trimming valuation assumptions. Benzinga: JPMorgan PT change
• Neutral Sentiment: Wells Fargo also trimmed its PT (from $38 to $35) but maintained an Overweight rating, another sign of cautious optimism. Benzinga: Wells Fargo PT change
• Neutral Sentiment: Independent analysis available — Seeking Alpha published a piece reviewing HeartFlow’s strategy and growth opportunities; useful for investors analyzing the longer‑term thesis. Seeking Alpha: HeartFlow: Getting Into The Flow
• Negative Sentiment: EPS miss and continued losses — HeartFlow reported GAAP EPS of ($0.29) vs consensus ($0.16), missing estimates and underscoring margin pressure and ongoing unprofitability (PE remains negative). MarketBeat: EPS miss / earnings details
• Negative Sentiment: Valuation and trend considerations — Despite the rally, the stock remains below its 50‑day and 200‑day moving averages and carries a wide range of analyst targets, indicating continued volatility and mixed near‑term sentiment. Benzinga: HTFL earnings & estimates

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.